|
|
|
|
|
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期- |
An Open Label, Multicenter, Dose-Finding Clinical Phase 1 Study of ASN004 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy in Patients With Advanced Malignant Solid Tumors
Participants in this study will receive ASN004 once every 3 or 4 weeks by intravenous infusion. The ASN004 dosing schedule may be modified based on emerging data and Safety Review Committee decision. The study will test various doses of ASN004 to find out the highest safe dose to test in future trials.
Eligible subjects will be sequentially enrolled in cohorts at escalated doses.
100 项与 Kirilys Therapeutics, Inc. 相关的临床结果
0 项与 Kirilys Therapeutics, Inc. 相关的专利(医药)
100 项与 Kirilys Therapeutics, Inc. 相关的药物交易
100 项与 Kirilys Therapeutics, Inc. 相关的转化医学